14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MAIA vs VRTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Vertex Pharmaceuticals Inc (VRTX) is the stronger overall head-to-head candidate over MAIA Biotechnology, Inc. (MAIA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MAIA carries a Unified Composite Score of 37.6/100 (SELL) at $1.11 (1.2x Forward P/E, 0.0% operating margin), whereas VRTX carries 40.9/100 (SELL) at $515.02 (25.9x Forward P/E, 37.8% operating margin).
Defensive Composite Rating Caution: Although VRTX compares more favorably head-to-head, both MAIA (37.6/100 SELL) and VRTX (40.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: MAIA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.8); meanwhile VRTX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MAIA vs VRTX. Trailing 12-month operating profitability (MAIA 0.0% vs VRTX 37.8%) and valuation multiples (MAIA 1.2x vs VRTX 25.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $68.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
VRTX Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $132.0B market capitalization and 37.8% operating margin.
OpEx & R&D Reinvestment17.0% of Rev ($2.20B)
90D Engineering Disclosures0 Published
Investor FAQ MAIA vs VRTX Key Questions & Quantitative Answers
As of Nov 20, 2026, Vertex Pharmaceuticals Inc (VRTX) is the stronger overall head-to-head candidate over MAIA Biotechnology, Inc. (MAIA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MAIA carries a Unified Composite Score of 37.6/100 (SELL) at $1.11 (1.2x Forward P/E, 0.0% operating margin), whereas VRTX carries 40.9/100 (SELL) at $515.02 (25.9x Forward P/E, 37.8% operating margin). Defensive Composite Rating Caution: Although VRTX compares more favorably head-to-head, both MAIA (37.6/100 SELL) and VRTX (40.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MAIA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.8); meanwhile VRTX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VRTX leads the Growth & Scale pillar: MAIA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VRTX at +11.8% YoY revenue growth and -39.0% YoY earnings growth on $13.0B TTM revenue (54.8% gross margin, 37.8% operating margin). On trailing 12-month operating scale, MAIA generates N/A in USD-normalized revenue versus $13.0B for VRTX. In operating R&D and SG&A reinvestment, MAIA deploys N/A (0 90-day corporate R&D disclosures) versus 17.0% of Rev ($2.20B) (0 disclosures) for VRTX.
MAIA screens cheaper on headline valuation multiples. MAIA trades at 1.2x Forward P/E, 1.2x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VRTX trades at 25.9x Forward P/E, 33.5x Trailing P/E, 2.34x PEG, and 10.3x EV/Revenue (24.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MAIA (-341.5% ROE) versus VRTX (20.8% ROE) capital efficiency.
In options market volatility and institutional positioning, MAIA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.65β · 108% Vol realized risk). By comparison, VRTX carries 115.6% implied volatility (33rd %ile, Balanced (25th–60th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.35β · 28% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.